Current Funding Opportunities – June 2015

TITLE: Smoking Cessation Within the Context of Lung Cancer Screening (R01)
(RFA-CA-15-011)
SPONSOR: National Cancer Institute
Synopsis: The goal of this Funding Opportunity Announcement (FOA) is to improve the effectiveness and/or implementation of smoking cessation interventions delivered to current smokers who undergo low-dose computed tomography (LDCT) lung cancer screening. The proposed projects must be aimed at determining: a) the key components and characteristics of an effective smoking cessation intervention delivered in the LDCT setting; and/or b) characteristics of an implementation strategy to optimally incorporate existing evidence-based smoking cessation intervention(s) into the LDCT setting. The projects must include prospective, comparative evaluation of the intervention(s) in terms of the rates of cessation and sustained abstinence (6-12 months after cessation) among current smokers undergoing screening. The LDCT screening site must be the essential context for the delivery of the cessation intervention, although interventions may also include services provided outside the site before or after screening.
Application Receipt/Submission Date(s): October 8, 2015

TITLE: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)
(PAR-15-266)
SPONSOR: National Cancer Institute
Synopsis: The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: FY15 Prostate Cancer Research Program (PCRP) Exceptional Responders Award
http://cdmrp.army.mil/funding/pcrp.shtml
SPONSOR: Department of Defense
Synopsis: The Health Disparity Research Award supports new ideas based on ***innovative*** concepts or methodologies for health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease. Studies proposed for this award mechanism are expected to improve the understanding of, and ultimately contribute to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. ***Applicants for this award must explicitly state how the proposed research is related***

to an area of prostate cancer health disparity. Appropriate health disparity areas include, but are not limited to, race and ethnicity; socioeconomic status; access to health care; differing standards of health care; insurance status; age; geography; sexual orientation; gender identity; and cultural beliefs.